Filing Flows › TriSalus Life Sciences (TLSI) › Q2 2026
TriSalus Life Sciences (TLSI) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 6, 2026
TriSalus Life Sciences (TLSI) reported revenue of $11.4M for the second quarter 2026 (Q2 2026), +2% from a year earlier and +28% from the quarter before. Operating margin was -86.0%, net loss $9.2M (80.5% of revenue).
TriSalus Life Sciences, Q2 2026: revenue $11.4M (+2% year over year), operating margin -86.0%, net loss $9.2M, operating cash flow −$10.1M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $11.4M | +28% | +2% |
| Operating profit | −$9.8M | — | — |
| Net earnings | −$9.2M | -697% | — |
| Operating cash flow | −$10.1M | — | — |
What changed
Revenue was $11.4M in Q2 2026, up 2% year over year and up 28% from the previous quarter.
Gross margin was 86.8%, up 2.9 points from Q2 2025. Operating costs exceeded revenue by $9.8M, an operating margin of -86.0%. Operating expenses grew 18% against revenue growth of 2%. The fastest-growing cost line was Sales & marketing (+59%). The quarter ended with a net loss of $9.2M, after a profit of $1.5M the previous quarter.
Operating cash flow was −$10.1M. Non-cash charges added back $136K of depreciation and amortization and $2.6M of share-based compensation. Working capital and other items used $3.7M. Capital expenditures of $82K exceeded it, leaving free cash flow of −$10.2M.
Questions
What was TriSalus Life Sciences' revenue in the second quarter 2026?
TriSalus Life Sciences (TLSI) reported revenue of $11.4M for the second quarter 2026 (Q2 2026), +2% from a year earlier and +28% from the quarter before.
Was TriSalus Life Sciences profitable in the second quarter 2026?
Operating loss was $9.8M (-86.0% of revenue) and net loss $9.2M.